These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15169794)

  • 21. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
    Jenkins AD; Ramondetta LM; Sun C; Johnston T; Wolf JK; Bodurka DC; Brown J; Atkinson EN; Levenback C
    Gynecol Oncol; 2005 Jun; 97(3):840-4. PubMed ID: 15882895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
    Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Comella P; Gambardella A; Farris A; Maiorino L; Natale D; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S;
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):133-9. PubMed ID: 15661564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
    Domingo E; Lorvidhaya V; de Los Reyes R; Syortin T; Kamnerdsupaphon P; Lertbutsayanukul C; Vito-Cruz E; Tharavichitkul E; Jin K; Yoshihara M; Cupino N; Lertsanguansinchai P
    Oncologist; 2009 Aug; 14(8):828-34. PubMed ID: 19661184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
    Bendell JC; Nemunaitis J; Vukelja SJ; Hagenstad C; Campos LT; Hermann RC; Sportelli P; Gardner L; Richards DA
    J Clin Oncol; 2011 Nov; 29(33):4394-400. PubMed ID: 21969495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
    Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Shields AF; Zalupski MM; Marshall JL; Meropol NJ
    Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
    McCollum AD; Wu B; Clark JW; Kulke MH; Enzinger PC; Ryan DP; Earle CC; Michelini A; Fuchs CS
    Am J Clin Oncol; 2006 Feb; 29(1):40-4. PubMed ID: 16462501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
    Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.